Altimmune's (ALT) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reiterated its "buy" rating for Altimmune (ALT) with a price target of $12.00, suggesting a potential upside of 213.32% from its previous close.
• Analysts have mixed opinions on the stock; while five analysts rate it as a buy, there are also sell and hold ratings from other firms like Goldman Sachs and Weiss Ratings.
• Altimmune's latest financial report showed an earnings per share (EPS) of ($0.27), exceeding estimates, but it still operates at a significant loss with a negative net margin.

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright's price target points to a potential upside of 213.32% from the stock's previous close.

Other research analysts have also issued reports about the stock. UBS Group cut their target price on shares of Altimmune from $26.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. The Goldman Sachs Group raised shares of Altimmune to a "strong sell" rating in a research note on Thursday, July 10th. Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. William Blair reissued a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Altimmune in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $17.40.

Altimmune Trading Down 1.5%

NASDAQ:ALT opened at $3.83 on Monday. The firm's fifty day moving average is $3.76 and its 200-day moving average is $4.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. Altimmune has a 52 week low of $2.90 and a 52 week high of $11.16. The firm has a market cap of $338.04 million, a P/E ratio of -3.25 and a beta of 0.07.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Equities analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in shares of Altimmune by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company's stock valued at $945,000 after acquiring an additional 2,162 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock valued at $247,000 after acquiring an additional 2,241 shares during the period. E Fund Management Co. Ltd. boosted its position in shares of Altimmune by 20.3% in the first quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company's stock valued at $67,000 after acquiring an additional 2,268 shares during the period. MetLife Investment Management LLC boosted its position in shares of Altimmune by 5.4% in the first quarter. MetLife Investment Management LLC now owns 46,870 shares of the company's stock valued at $234,000 after acquiring an additional 2,396 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company's stock valued at $108,000 after acquiring an additional 2,748 shares during the period. Hedge funds and other institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.